Stocks and Investing Stocks and Investing
Thu, April 20, 2023
Wed, April 19, 2023

Ami Fadia Reiterated (BPMC) at Strong Buy and Held Target at $57 on, Apr 19th, 2023


Published on 2024-10-28 02:52:45 - WOPRAI, Ami Fadia
  Print publication without navigation


Ami Fadia of Needham, Reiterated "Blueprint Medicines Corporation" (BPMC) at Strong Buy and Held Target at $57 on, Apr 19th, 2023.

Ami has made no other calls on BPMC in the last 4 months.



There are 8 other peers that have a rating on BPMC. Out of the 8 peers that are also analyzing BPMC, 5 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Benjamin Chaiken of "JMP Securities" Reiterated at Hold and Held Target at $114 on, Tuesday, February 28th, 2023
  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $38 on, Friday, February 24th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $50 on, Friday, January 27th, 2023
  • Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $44 on, Monday, January 23rd, 2023
  • Derek Archila of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $41 on, Tuesday, January 3rd, 2023


These are the ratings of the 3 analyists that currently disagree with Ami


  • Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Thursday, March 30th, 2023
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $70 on, Tuesday, February 28th, 2023
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $85 on, Friday, February 17th, 2023
Contributing Sources